William Febbo Net Worth

The estimated Net Worth of William J Febbo is at least $12.4 Million dollars as of 18 April 2024. Mr. Febbo owns over 28,895 units of OptimizeRx Corp stock worth over $4,237,215 and over the last 8 years he sold OPRX stock worth over $7,301,875. In addition, he makes $833,990 as Chief Executive Officer und Director at OptimizeRx Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Febbo OPRX stock SEC Form 4 insiders trading

William has made over 24 trades of the OptimizeRx Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 28,895 units of OPRX stock worth $210,356 on 18 April 2024.

The largest trade he's ever made was exercising 394,739 units of OptimizeRx Corp stock on 24 March 2021 worth over $1,267,112. On average, William trades about 23,789 units every 84 days since 2016. As of 18 April 2024 he still owns at least 582,035 units of OptimizeRx Corp stock.

You can see the complete history of Mr. Febbo stock trades at the bottom of the page.

William Febbo biography

William J. Febbo serves as Chief Executive Officer, Director of the Company. Mr. Febbo brings more than 20 years of experience in building and managing health services and financial businesses. Before joining our company. From 2007 to 2015, he worked with Merriman Holdings, Inc., an investment banking firm. There he served as Chief Operating Officer and assisted with capital raises in the tech, biotech, cleantech, consumer and resources industries. Prior to Merriman, Mr Febbo was CEO and co-founder of MedPanel, a provider of market intelligence and communications for the pharmaceutical, biomedical, and medical device industries, which was eventually acquired by MCF Corporation. Mr. Febbo holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania. Febbo serves on the board of The United Nations of Greater Boston, a non-profit focused on building global citizens within inner-city schools in Massachusetts, is faculty on the MIT linq program and currently serves as a board member of Modular Medical (MODD).

What is the salary of William Febbo?

As the Chief Executive Officer und Director of OptimizeRx Corp, the total compensation of William Febbo at OptimizeRx Corp is $833,990. There are 1 executives at OptimizeRx Corp getting paid more, with Stephen Silvestro having the highest compensation of $1,210,200.

How old is William Febbo?

William Febbo is 51, he's been the Chief Executive Officer und Director of OptimizeRx Corp since 2016. There are 11 older and 2 younger executives at OptimizeRx Corp. The oldest executive at OptimizeRx Corp is Gus Halas, 69, who is the Chairman of the Board.

What's William Febbo's mailing address?

William's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02453.

Insiders trading at OptimizeRx Corp

Over the last 2001 years, insiders at OptimizeRx Corp have traded over $20,012,815 worth of OptimizeRx Corp stock and bought 258,753 units worth $1,128,145 . The most active insiders traders include Investment Company, Inc. Awm, Bradley Louis Radoff und David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of $183,485. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth $73,244.

What does OptimizeRx Corp do?

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.

Complete history of Mr. Febbo stock trades at OptimizeRx Corp

OptimizeRx Corp executives and stock owners

OptimizeRx Corp executives and other stock owners filed with the SEC include:

• Stephen Silvestro,
  Chief Commercial Officer
• William Febbo,
  Chief Executive Officer, Director
• William J. Febbo,
  CEO & Director
• Stephen L. Silvestro,
  Chief Commercial Officer
• Miriam Paramore,
  President
• Douglas Baker,
  Chief Financial Officer
• Gus Halas,
  Chairman of the Board
• Lynn Vos,
  Independent Director
• Patrick Spangler,
  Independent Director
• James Lang,
  Independent Director
• Angelo Campano,
  Senior Vice President - Principal of Agency Channels
• Ron Both,
  Investor Relations
• Gregory Wasson,
  Director
• Todd Inman,
  Chief Technology Officer
• Maira Alejandra,
  Media Relations Mang.
• Todd Inman,
  Chief Technology Officer
• Andrew Jacob D'Silva,
  Sr. VP of Corp. Fin.
• Douglas P. Baker,
  Exec. VP of Fin. & Accounting
• Edward Stelmakh C.M.A., M.B.A., MBA,
  CFO & COO
• Rebecca Whitney,
  Sr. VP of Commercial Operations
• Terence J. Hamilton,
  Sr. VP of Pharma
• Sheryl Kearney,
  HR Mang.
• Marion K Odence-Ford,
  Gen. Counsel & Chief Compliance Officer
• Cathy Klema,
  Director
• Ellen O'connor Vos,
  Director
• Plc Wpp Luxembourg Gamma Th...,
  
• Investment Company, Inc. Awm,
  10% owner
• Bradley Louis Radoff,
  10% owner
• Jack T Pinney,
  Director
• Richard Kraniak,
  10% owner
• David Lester,
  Chairman of the Board
• David Harrell,
  Chief Executive Officer
• Terrence Hamilton,
  Vice President
• James M Brooks,
  SVP of Business Development
• Brian J Dillon,
  SR. VP OF PRODUCT & STRATEGY
• Brian Clark Mc Carthy,
  Chief Revenue Officer
• Marion Odence Ford,
  General Counsel and CCO
• Edward Stelmakh,
  CFO/COO
• Doug Besch,
  Chief Product Officer
• Theresa Greco,
  Chief Commercial Officer